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Xiao-Ming Lin1, Chuang Chi1, Jun Chen3, Yu Liu1, Peng Li4 and Yi Yang2*Abstract
Primary pleural squamous cell carcinoma is very rare, and there is a lack of experience in the diagnosis and
treatment of this condition. An asymptomatic 75-year-old man was referred to us after a right pleural nodule was
found on computed tomography during a routine health examination. He underwent surgery for his pleural tumor
twice over the following 2 years. Histopathological examination eventually led to a diagnosis of primary pleural
squamous cell carcinoma.
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Primary pleural squamous cell carcinoma (SCC) is very
rare [1]. A review of the literature did not find any
recently reported cases. As patients are generally asymp-
tomatic in the early stage and computed tomography
(CT) shows local pleural thickening or small nodules,
primary pleural SCC is easily misdiagnosed as localized
mesothelioma. The histopathological features of these
two tumors are also similar.
Unfortunately, pleural SCC and localized mesothelioma
have different oncological characteristics. Localized meso-
thelioma usually has a good prognosis [2], but pleural
SCC is characterized by malignant tumor growth with in-
vasion of the surrounding tissues and organs, and metasta-
sis. Delays in correct diagnosis and appropriate treatment
therefore have serious clinical consequences and result in
poor prognosis.Case presentation
In August 2009, a 75-year-old man (Chinese, ethnic Han)
was referred to our clinic after a right pleural nodule was
found on chest CT during a routine health examination.
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reproduction in any medium, provided the orunremarkable. Chest CT showed a soft tissue nodule with
homogeneous enhancement arising from the right pleura,
measuring 31 × 15 mm. The nodule had clearly demar-
cated margins and there was no evidence of invasion into
the adjacent ribs. There was no enlargement of medias-
tinal lymph nodes (Figure 1). Video-assisted thoracic sur-
gery (VATS) revealed a smooth nodule on the parietal
pleura at the fourth intercostal space, measuring 35 ×
20 mm and not adherent to the adjacent lung. The nodule
was completely resected. Postoperative histopathological
examination revealed fibrous tissue hyperplasia with
inflammatory cell infiltration and mesothelial cell proli-
feration, and a diagnosis of pleural mesothelioma was
made (Figure 2). The patient recovered quickly and was
discharged from hospital on the seventh day after surgery.
In April 2011, he presented again with a 2-month
history of right-sided chest pain, cough, sputum pro-
duction, fatigue and weight loss. Physical examination
revealed right chest wall tenderness and a hard, poorly
delineated mass at the fourth intercostal space. Chest
CT revealed right anterolateral pleural thickening, a soft
tissue shadow in the adjacent chest wall, and clear lung
fields with no enlargement of the mediastinal lymph
nodes (Figure 3). Based on imaging findings, he was
thought to have recurrence of pleural mesothelioma.
Preoperative tumor antigen testing detected an elevated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 First chest CT scan on 29 August, 2009.
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(normal value < 1.5 μg/m1).
We performed right thoracotomy through the fourth
intercostal space. The tumor in the subcutaneous tissues
measured 5 × 4 × 4 cm, and was continuous with a
pleural lesion measuring 7 × 8 × 8 cm, which had poorly
demarcated margins and had invaded the upper lobe of
the right lung. Intraoperative biopsy of the pleural tumor
revealed primary pleural SCC. En bloc resection of the
tumor was performed, including the chest wall, pleura,
part of the right upper lobe, part of the fourth and fifth
ribs, and tissues of the intercostal space. Postoperative
histopathological examination revealed areas of pleo-
morphic tumor cells with large nuclei and reduced cyto-
plasm. These features were consistent with stage I SCC
(Figure 4). The patient recovered well. One month after
operation, he returned to the hospital and received a
50Gy local radiation therapy. In October, 2012, his chestFigure 2 Pathological specimen from the first operation
(hematoxylin and eosin staining, × 40).CT showed that the operation area was in good condi-
tion (Figure 5).
Discussion
The majority of pleural tumors are metastases from
primary tumors in organs such as the lung or breast [3].
Primary pleural tumors are rare, and are usually diffuse
or localized mesotheliomas [4]. Primary pleural SCC is a
particularly rare pleural malignancy which has seldom
been reported.
Because of similar morphology, early primary pleural
SCC may be misdiagnosed as localized mesothelioma,
especially solitary fibrous tumor (SFT) of the pleura.
However, these two conditions have different progres-
sion and prognosis. In order to avoid misdiagnosis and
inappropriate treatment, it is necessary to distinguish
between the two carefully.
SFT of the pleura is also uncommon, accounting for 4%
of all pleural neoplasms [5]. SFT is not associated with
asbestos exposure and usually has a good prognosis [2].
According to reviews by Briselli et al. [6] and England
et al. [7], 12% to 33% of SFTs of the pleura were consid-
ered to be malignant according to their pathological char-
acteristics. Due to the extreme rarity of primary pleural
SCC, its incidence is not described in the literature, and
the cause of this disease is unclear. We performed a litera-
ture search and found that SCC arising from the pleura
had been reported in a few patients with chronic post-
pneumonectomy bronchopleural fistulas [1]. Chronic
pleural inflammation may therefore be one of the causes
of primary pleural SCC.
Early pleural SCC that has not invaded the surround-
ing structures is usually asymptomatic. As the disease
progresses, some atypical symptoms may appear, such as
chest pain, cough, sputum production, weakness and
weight loss. Early pleural SFT is also asymptomatic [8,9],
Figure 3 Second chest CT scan on 18 April, 2011.
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festations. Hypertrophic osteoarthropathy is observed in
about 20% of cases, which may result from production of
hyaluronic acid or hepatocyte growth factor by the tumor
[10-12]. Hypoglycemia occurs in 2% to 4% of cases and is
thought to be due to production of insulin-like growth fac-
tor II (IGF-II), which lowers the blood glucose level and
impairs the growth hormone counter-regulatory response
to hypoglycemia [12]. Hemorrhagic pleural effusions may
occur in advanced pleural SCC, and serous pleural effu-
sions may occur in about 10% of cases of pleural SFT [9].
These different symptoms of the two diseases may help to
differentiate them.
The lack of specific features makes it difficult to differ-
entiate between early primary pleural SCC and early
pleural SFT on preoperative imaging examinations such
as chest radiography and computed tomography [8,10].
These imaging modalities can show the locations of theFigure 4 Pathological specimen from the second operation
(hematoxylin and eosin staining, × 100).lesions but cannot distinguish between benign and ma-
lignant lesions. Whole-body 18 F-deoxyglucose (FDG)-
positron emission tomography (PET) has become a
popular imaging modality in recent years, and can accur-
ately differentiate benign from malignant tumors, as
FDG uptake is very high in malignant tumors [13,14].
Preoperative biopsy is important for the diagnosis of
pleural tumors. The reported rate of accurate diagnosis on
CT-guided fine needle aspiration is about 45% in some
series [10,11]. However, transthoracic Tru-Cut needle
biopsy can obtain more tissue for histological and immu-
nohistochemical analysis, and may be a better choice [5].
When the nature of pleural nodules is difficult to deter-
mine, such invasive examinations may be useful.
Several tumor markers may also be helpful for deter-
mining the type of pleural tumor. P63 is always negative
in cases of mesothelioma and almost always positive in
cases of SCC [15]. Calretinin is considered to be one of
the best markers for differentiating between mesotheli-
oma and other thoracic neoplasms, as it is strongly and
diffusely positive in all types of mesothelioma, and gen-
erally negative or only focally positive in other types of
neoplasm [16]. A number of studies have reported that
cytokeratin 19 fragment (CYFRA 21–1) is the most sen-
sitive biomarker for SCC, and another biomarker of the
cytokeratin family had also demonstrated good diagnos-
tic ability [17]. Although SCC antigen (SCCA) has a
lower sensitivity than CYFRA 21–1, it has higher specifi-
city for SCC [17]. Our patient tested positive for SCCA.
Surgery is the preferred method of treatment for
pleural nodules. Cardillo et al. [10] reported that 87% of
SFTs originated in the visceral pleura and only 13% in
the parietal pleura. Most SFTs have well-demarcated
margins and do not invade the surrounding structures,
and complete surgical resection is not difficult. Early pri-
mary pleural SCC is also treated by surgical excision. It
Figure 5 Third chest CT scan on 18 October, 2012.
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pleura, because of the small number of reported cases.
VATS is the preferred procedure for excision of pleural
nodules because it is minimally invasive. The surgical
treatment of choice is local excision with intraoperative
assessment of the surgical margins [10]. If tumor-free sur-
gical margins cannot be obtained using VATS, the proced-
ure should be converted to open thoracotomy [9-11]. For
some parietal pleural nodules with unclear edges which
are suspicious for malignancy, intraoperative frozen sec-
tion examination should be performed to help decide
whether to perform extended resection to reduce the risk
of recurrence and improve prognosis [9-11]. Postoperative
adjuvant therapy for pleural malignancy has seldom been
reported in the literature.
Some reports have suggested that CT should be per-
formed every 6 months for the first 2 years after excision of
pleural tumors to monitor for recurrence. Most recurrences
of malignant pleural tumors occur within 24 months of the
initial resection. Recurrence rates after complete resection
were reported to be 8% in patients with benign pleural SFT
and 63% in patients with malignant pleural SFT [18]. Fur-
ther observation is required to determine whether patients
with primary pleural SCC require the same follow-up after
resection as those with pleural SFT.
For recurrent pleural SFT, repeat surgical resection
may be the first choice of treatment, and is associated
with good cure rates [19]. If recurrent pleural tumors
are inoperable, then local radiotherapy and systemic
chemotherapy should be given, although the optimal
regimens have not been established [20]. Recent reports
indicate that treatment with ifosfamide and doxorubicin
may be effective. Observation of further cases is needed
to determine whether the radiotherapy and chemother-
apy regimens used for recurrent lung SCC are also
effective in cases of primary pleural SCC.Conclusion
Primary pleural SCC is very rare. Because of the lack of
clinical experience, early primary pleural SCC is easily
misdiagnosed as localized mesothelioma, leading to de-
layed or inappropriate treatment. However, SCC can be
diagnosed by preoperative investigations such as FDG-
PET, measurement of tumor markers, and transthoracic
Tru-Cut needle biopsy. The prognosis of this disease is
not clear at present.
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